Viking Global Investors and Perceptive Advisors stand to benefit from the planned initial public offering of BridgeBio Pharma, a drug company in Palo, Alto California that was founded in 2015.
Hedge fund firm Viking Global Investors and KKR & Co. each own at least five percent of its shares, according to a preliminary IPO prospectus that BridgeBio filed May 24 with regulators.